Tufts University's Dental School Will Conduct Formal Clinical Study to Provide Access to a US Market of 10 Million Surgeries Per Year
BioElectronics Corporation (PINKSHEETS: BIEL), developers of innovative pain-relieving medical devices, today announces it has been awarded a major grant from the U.S. government that will complete funding for a study on the effectiveness of Pulsed Electromagnetic Field (PEMF) therapy in reducing oral surgery pain. BioElectronics is combining its Therapeutic Discovery Project Grant with its own monies to conduct the study through the Tufts University School of Dental Medicine, one of the nation's leading dental research centers. The Grant qualification criteria was "show the greatest potential to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in life, biological and medical sciences."
Neophytos Demetriades D.D.S., Assistant Professor of the Oral & Maxillofacial Surgery Department at the Tufts school, will direct the project entitled "Evaluation of Edema and Pain Following Third Molar Extraction with RecoveryRx Treatment." Dr. Demetriades, primary investigator, is a member of the American Association of Oral and Maxillofacial Surgeons, and a fellow of the International Association of Oral and Maxillofacial Surgeons.
"BioElectronics was founded on the idea that we change the way people heal. This grant, we believe, will not only help to advance that philosophy, but also potentially substantiate a remarkable new therapy that can bring relief to millions and significant revenues for BioElectronics," said Arnon Horev, Vice President of Sales and Marketing at BioElectronics Corporation.
Ten million third molars are extracted from approximately 5 million people in the United States each year at an annual cost of over $3 billion. In addition, more than 11 million patient days of "standard discomfort or disability" -- pain, swelling, bruising, and malaise -- result postoperatively from third molar extractions.
The BioElectronics/Tufts study, expected to commence immediately, will be a randomized, within-subject controlled, double blind, placebo- and positive-controlled clinical trial conducted through the university by Dr. Demetriades and his team.
Upon completion of the study, the data will be used for U.S. FDA submission to gain additional clearances and to support the Company's sales and marketing efforts. For more information about RecoveryRx, go to www.bielcorp.com (http://www.bielcorp.com) .
In addition to the research grant, BioElectronics received a grant from the State of Maryland, under the Export MD process, to exhibit at Medica in Dusseldorf, Germany. Medica is the world's largest medical device exhibition, connecting thousands of manufacturers and distributors internationally. For more information about Medica, go to http://www.mdna.com/shows/medica.htmlâ€¥pagepage-1 (http://www.mdna.com/shows/medica.htmlâ€¥pagepage-1)
About BioElectronics Corporation BioElectronics Corporation (PINKSHEETS: BIEL) is the maker of safe, inexpensive, drug-free medical devices and patches that deliver pulsed electromagnetic energy to relieve pain and inflammation. The company's wafer thin patches contain an embedded microchip and battery that deliver pulsed electromagnetic energy, a clinically proven and widely accepted anti-inflammatory and pain relief therapy that heretofore has only been possible to obtain from large, facility-based equipment. BioElectronics markets and sells its current products under the brand names ActiPatch, RecoveryRx, Allay Menstrual Pain Therapy and HealFast Therapy for cats, dogs and horses. The company is headquartered in Frederick, MD. For more information, visit www.bielcorp.com (http://www.bielcorp.com) .